Uterine cancer is currently the only cancer type not covered by the World Trade Center (WTC) Health Program.
The World Trade Center (WTC) Health Program announced it is considering adding uterine cancer to the List of WTC-Related Health Conditions according to a recently published Notice of Proposed Rulemaking. Uterine cancer is currently the only cancer type not covered by the WTC Health Program.1
This notice proposes every type of uterine cancer, including endometrial cancer, be added to the 9/11-related health conditions list. By including uterine cancer in the List, it would grant the WTC Health Program the ability to offer treatment to members who have 9/11-related uterine cancers.
“We know that WTC Health Program members continue to face health challenges that stem from their exposures on or in the months after 9/11,” said John Howard, MD, administrator of the WTC Health Program and director of the National Institute for Occupational Safety and Health. “The proposed rule published today in the Federal Register is the next step toward ensuring women who are enrolled in the WTC Health Program have access to the cancer care and treatment they need if their uterine cancer is related to their 9/11 exposures.”
For more information on the WTC Health Program, visit www. CDC.gov/WTC.
Reference
1. The world trade center health program proposes rulemaking to add uterine cancer to the list of world trade center-related conditions. NIOSH. CDC . Published May 10, 2022. Accessed June 3, 2022. https://www.cdc.gov/niosh/updates/upd-05-10-22.html
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More
2 Commerce Drive
Cranbury, NJ 08512